Business Context and Reporting Period
This Form 8-K Current Report was filed by Marchex, Inc. on May 7, 2010. The filing discloses material definitive agreements regarding equity compensation and changes in corporate leadership effective as of the 2010 annual stockholder's meeting.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on equity grant details and executive appointments.
Material Changes
- Executive Leadership Change: John Keister's position was changed from President to Executive Vice Chairman of the Board of Directors, effective May 7, 2010.
- Non-Employee Director Grants: An aggregate of 46,000 restricted shares of Class B common stock were granted to non-employee directors at a purchase price of $0.01 per share. These shares vest 100% one year from the grant date, subject to continued service.
- Executive Vice Chairman Grants: John Keister received 45,000 shares of restricted stock and a stock option grant for 45,000 shares.
- Restricted Stock: Vests 25% annually over four years.
- Stock Options: Exercise price based on the closing price on May 11, 2010. Vesting begins 25% on the first anniversary, with the remainder vesting quarterly over the subsequent three years.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. It notes that 100% of unvested options and restricted stock for John Keister will accelerate upon a Change of Control followed by termination without cause, a Diminution in Duties, or the 12-month anniversary of the Change of Control.
Investor Verification Checklist
- Verify the total number of shares authorized under the 2003 Amended and Restated Stock Incentive Plan to assess remaining capacity for future grants.
- Confirm the closing price of Class B common stock on May 11, 2010, to determine the exercise price for Keister's stock options.
- Review the specific definitions of "Change of Control" and "Diminution in Duties" in the attached executive agreements to understand acceleration triggers.
- Check subsequent periodic reports (10-Q or 10-K) for the impact of these grants on the company's stock-based compensation expense.